Peptides and Testosterone: What the Research Actually Shows

In 1978, Ernst Knobil's laboratory took rhesus monkeys whose reproductive hormones had been shut off by hypothalamic lesions and tried to restart them with synthetic GnRH. A steady, continuous supply did nothing at all. The same hormone, delivered once an hour, brought the whole system back to life, and it could be made to collapse again by returning to the steady supply (PMID: 100883). That one experiment explains almost everything about why this subject is so confusing. What Knobil's group actually measured was LH and FSH, the two hormones the pituitary sends out, in monkeys whose own gonads had been removed — and that is precisely why it matters here, because LH is the single instruction that tells the testes to make testosterone. The amount of signal was not what counted. The rhythm was. Every link in that chain above the testis is a peptide, which is why researchers working on the system reach for compounds like Gonadorelin Acetate and Kisspeptin-10. Both sit in our Endocrine & Hormonal research peptides range.

This guide separates the peptides that have actually moved testosterone in published human studies from the ones talked about as though they had. The first group is small, specific and genuinely interesting; the second is much more famous. Along the way: the axis in plain English, what each named study measured and in whom, the awkward finding that one well-known peptide pathway pushes testosterone down, and the questions nobody has answered yet. Every Crown Peptides compound named below is supplied for laboratory research only, and what follows is a tour of what has been measured rather than a verdict on what it means.

Testosterone Is Not a Peptide, So Why Is This a Peptide Question?

Start with the molecule, because this is where the subject first goes wrong. Testosterone is a steroid, built from cholesterol by a chain of enzymes, small enough and fatty enough to slip straight through a cell membrane and act on DNA inside the cell. It is not a chain of amino acids, and no amount of searching will turn it into one. Our guide Peptides vs Steroids sets the two classes of compound side by side.

But here is what makes the question reasonable rather than confused. Testosterone is the output of the system, and every instruction above it is a peptide. So the honest answer is neither "peptides have nothing to do with it" nor "here are five that will raise it". It is that the control system is built from peptides, and a handful of them have been studied in people with testosterone as a measured outcome.

Three glands, one conversation

The chain is the hypothalamic-pituitary-gonadal axis, or HPG axis, and it works like a relay with three runners. The hypothalamus releases gonadotropin-releasing hormone, GnRH, a ten-amino-acid peptide, which travels a few millimetres down a dedicated set of blood vessels to the pituitary. The pituitary answers by releasing two hormones into the general circulation: luteinising hormone and follicle-stimulating hormone, LH and FSH. LH reaches the testes and binds a receptor on the Leydig cells, which respond by making testosterone from cholesterol. FSH acts on the Sertoli cells, which support sperm production.

Then the loop closes. Testosterone, and the oestradiol made from it, travel back up to the hypothalamus and pituitary and turn the volume down. A thermostat, not a tap.

Why the dial is really a drumbeat

Knobil's experiment was only the start. Three years later the same group kept the pulses and changed only their timing. In ovariectomised rhesus monkeys with hypothalamic lesions, running the pulses faster — two, three or five an hour in place of the natural one — made circulating LH and FSH decline instead of rise. Stretching the gap to three hours cut LH by variable amounts while FSH went up in every animal (PMID: 6788538).

Read that again, because it is the single most useful fact in the field. The same hormone, in the same amount, produces more LH or more FSH purely according to how often it arrives. A system built that way cannot be nudged by adding more of something; it has to be spoken to in its own rhythm. The full story of GnRH itself — the two laboratories that raced to isolate it from hundreds of thousands of pig hypothalami, and what each one found — is in What Is GnRH?, and Peptide Hormones Explained covers why peptide hormones vanish so fast.

The ten amino acids at the top of it all

In June 1971, Schally's group put a proposed sequence for the pig releasing hormone into print (PMID: 4936338). Ten residues, standing above the whole reproductive system. Purified LH-RH had already been given to people, in amounts chosen more or less arbitrarily; what the dose-response study published that same year added was how little was needed to raise serum LH, and how orderly the relationship turned out to be (PMID: 4932985).

The synthetic version of that decapeptide is gonadorelin, which is why Gonadorelin Acetate turns up in so much HPG-axis work. It is not an analogue with chemistry bolted on; it is the sequence itself, so a researcher using it asks the pituitary exactly the question the hypothalamus asks. Our Gonadorelin guide covers it in detail.

The Same Molecule Can Switch the Axis On or Shut It Down

Now the twist. If pulses switch the system on, what does an unrelenting GnRH signal do? Knobil's group had already seen the answer in monkeys: the pituitary stops listening (PMID: 100883). Build a GnRH analogue that survives in the blood long enough to be effectively continuous, and you get the opposite of stimulation.

That is precisely how GnRH agonist medicines work. Reporting on men with carcinoma of the prostate, Santen and Warner described leuprolide suppressing pituitary LH and FSH and, as a consequence, testicular testosterone and dihydrotestosterone, writing that it simulated the results achieved with surgical castration (PMID: 3918377). A randomised trial in 199 men with metastatic disease found testosterone suppression comparable to diethylstilbestrol (PMID: 6436700). Developed separately as medicines, GnRH agonists such as leuprorelin, goserelin and triptorelin are licensed in the UK and many other countries for prostate cancer and other indications.

That is the crucial context for the whole subject. The same receptor, given the same message in a different rhythm, can drive the axis or silence it. Not a quirk: the design.

Then Someone Found the Switch Above the Switch

For thirty years GnRH looked like the top of the chain. It was not. The clue arrived from families in whom puberty simply never started.

In 2003, Stephanie Seminara and a transatlantic team found affected members of a consanguineous family with idiopathic hypogonadotropic hypogonadism to be homozygous for a mutation in a G protein-coupled receptor gene called GPR54. Mice engineered to lack the same receptor had small testes, delayed sexual development and low gonadotropins, yet responded perfectly well to GnRH given from outside and had normal GnRH levels in the hypothalamus (PMID: 14573733). The machinery was intact. The instruction to use it was missing. Nine years later, Ali Kemal Topaloglu's group closed the loop from the other end, describing an inactivating mutation in KISS1, the gene for the peptide itself, in a large consanguineous family in which pubertal progression failed (PMID: 22335740).

Peptide or receptor, lose either and the axis never starts. That peptide is kisspeptin, and Kisspeptin-10 is its shortest fully active fragment. Our article Kisspeptin-10: The Peptide That Turned Out to Be the Master Switch for Puberty tells the discovery story properly.

What happened when kisspeptin was given to men

This is where the subject stops being theoretical. In 2005, a team at Imperial College London ran a double-blind, placebo-controlled crossover study in six male volunteers, each receiving a 90-minute intravenous infusion of kisspeptin-54 and a saline control in random order. Plasma LH, FSH and testosterone all rose: mean LH over 90 minutes was 10.8 U/l against 4.2 on saline, FSH 3.9 against 3.2, and mean testosterone over 180 minutes 24.9 nmol/l against 21.7, each at P < 0.001 (PMID: 16174713). Six men, one afternoon, the whole axis moved.

In 2011, an Edinburgh group led by Jyothis George tested the shorter fragment. Intravenous boluses of kisspeptin-10 in six healthy men produced a rapid, dose-dependent rise in serum LH, from 4.1 to 12.4 IU/l at 30 minutes at the most effective level, with a smaller response at the highest level tested. In four men given a continuous 22.5-hour infusion, mean LH went from 5.4 to 20.8 IU/l and serum testosterone from 16.6 to 24.0 nmol/l. A gentler infusion revealed the mechanism: LH pulse frequency rose from 0.7 to 1.0 pulses an hour, and the mass of each secretory burst more than trebled (PMID: 21632807).

Note what those two studies did and did not establish. Both enrolled small numbers of men with normal baseline hormones, and both ran over hours. They show kisspeptin raising LH and testosterone in healthy men over a short window, and were never designed to show anything about people with low testosterone.

How does kisspeptin compare with GnRH head to head?

In 2013 the Imperial group ran exactly that experiment. Healthy men received vehicle, kisspeptin-10, kisspeptin-54 and GnRH intravenously for three hours on separate days, five men per dosing group, with LH and FSH measured throughout. GnRH won comfortably: serum LH and FSH were roughly three-fold higher during GnRH infusion than during kisspeptin-10, and about two-fold higher than during kisspeptin-54 (PMID: 26089302). The authors noted the small sample size, and added that kisspeptin may still stimulate gonadotropins in a more physiological way. The reason is structural: it works through the body's own GnRH neurons rather than bypassing them. Hence both on the shelf — GnRH speaks to the pituitary, kisspeptin speaks to the hypothalamus and lets it decide.

A pulse generator you can actually reset

Yee-Ming Chan and colleagues at Massachusetts General Hospital gave thirteen healthy adult men a single intravenous bolus of the C-terminal decapeptide of kisspeptin and watched the clock. It triggered an immediate LH pulse no matter when the previous natural one had happened, and the induced pulses were larger than spontaneous ones, amplitude 5.0 against 2.1 mIU/ml. Most striking of all, it reset the generator: the next natural pulse was pushed back by roughly a full interval (PMID: 21470997). It was the first agent ever shown to do it.

What happens if the signal never stops?

Given what continuous GnRH does, the obvious question is whether continuous kisspeptin behaves the same way. At Massachusetts General Hospital, three healthy men received a continuous 24-hour intravenous infusion of kisspeptin-10. LH climbed immediately, from a baseline of 2.8 to 3.8 mIU/ml up to peaks of 17.5 to 30.6, reached within 12 to 20 hours. Then it drifted, falling by 13 to 47% from its maximum by the end of the infusion, while FSH and testosterone rose modestly in parallel (PMID: 42230485). Three men is three men, but that curve is what you would expect from a receptor that prefers to be spoken to intermittently.

The Imperial group then tested the obvious fix, in a randomised, single-blinded, placebo-controlled study across fifteen healthy men with twelve controls. Five days of continuous infusion gave a split result: testosterone stayed elevated, but gonadotropins ended up similar to vehicle. Daily eight-hour infusions with sixteen hours off, run for twelve days, sustained the gonadotropin rise instead, and a bolus on day twelve still produced a rise, showing the receptor remained functional (PMID: 42549827). On and off beats always on. The axis has not changed its mind about rhythm.

One of the neatest applications has nothing to do with raising anything: GnRH tests the pituitary, kisspeptin tests the hypothalamus above it, so together they reveal which floor a fault is on. Given to 21 men with congenital hypogonadotropic hypogonadism and 21 healthy men, kisspeptin-54 produced a maximal LH rise of 12.5 iU/l in the healthy group and 0.4 iU/l in the affected one, with no overlap at all (PMID: 33227799).

Now the Awkward Part: The Peptides People Actually Search For

Search for peptides for testosterone and you will mostly be shown growth hormone peptides. Sermorelin. CJC-1295. Tesamorelin. Ipamorelin. GHRP-2. They are superb research compounds with a deep published record. They also act on a completely different axis, and no published study of them reports a rise in testosterone — in most cases because testosterone was never measured at all. One of them did go looking, and that is the most useful fact in this section.

The growth hormone axis runs hypothalamus to pituitary to liver and tissues, through growth hormone and IGF-1; the reproductive axis runs hypothalamus to pituitary to gonads. They share a gland and little else. Our hub article Growth Hormone Peptides Explained maps that family properly.

What the growth hormone peptide studies actually measured

Open their trial papers and the same thing happens every time. The outcome measures are growth hormone, IGF-1, body fat or height. Testosterone is not on the list.

The two CJC-1295 (With DAC) trials in healthy adults aged 21 to 61 named peak concentration and area under the curve of GH and IGF-I as their main outcome measures, and a single subcutaneous dose raised mean plasma GH two- to ten-fold for six days or more (PMID: 16352683) — our CJC-1295 with DAC guide has the pharmacology, and Peptide Half-Life Explained covers the 5.8-to-8.1-day half-life behind it. Tesamorelin, whose story our Tesamorelin guide tells, has the largest trial of any GHRH analogue — 412 people with HIV, 86% of them men, 26 weeks — with visceral fat on CT as its primary endpoint, down 15.2% against a 5.0% rise on placebo, IGF-I and blood lipids among the secondary endpoints, and testosterone nowhere in the list (PMID: 18057338). The Sermorelin evidence that matters most is paediatric: in sixteen prepubertal children with growth hormone deficiency given a single daily subcutaneous dose of GHRH(1-29), 68.7% were judged good responders, with growth velocity in that group rising from 3.4 to 6.8 cm a year by six months (PMID: 7735367), and our Sermorelin guide covers the compound.

Three compounds, three sets of endpoints, no gonadal hormones anywhere. Developed separately as a medicine, tesamorelin is approved in the United States under the name Egrifta for excess abdominal fat in HIV-associated lipodystrophy.

Then there is the exception, hiding in the 1998 paper that introduced Ipamorelin. Novo Nordisk's team characterised the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2 across cell, rat and swine work, and deliberately checked its specificity. In swine, none of the growth hormone secretagogues tested affected plasma FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 raised ACTH and cortisol, while ipamorelin did not move them beyond what GHRH itself did (PMID: 9849822). Somebody looked specifically at whether these compounds touch LH and FSH in a large mammal, and in that experiment they did not. Our Ipamorelin guide has the rest.

The ghrelin pathway pushes the other way

Here the story gets genuinely surprising. Ipamorelin, GHRP-2, GHRP-6 and Hexarelin Acetate all work at the ghrelin receptor, GHS-R1a. So what does ghrelin itself do to the reproductive axis in humans?

In 2007, Michael Kluge's group in Munich measured overnight LH and testosterone profiles in ten healthy young men on two separate nights in a single-blind, randomised, crossover design, giving ghrelin or placebo at four points through the night. Ghrelin was associated with significantly lower mean LH and testosterone than placebo. The first LH pulse afterwards had a smaller peak, 2.98 against 4.37 mIU/ml; the gap between pulses stretched from 191 to 256 minutes; and fewer pulses occurred overall (PMID: 17550958).

A Turin group then located where that happens. In seven young healthy men, infusing acylated ghrelin suppressed LH levels and abolished LH pulsatility altogether, with no change in FSH. Crucially, the LH and FSH responses to a GnRH bolus were completely unaffected. The pituitary was fine; the inhibition was happening above it (PMID: 18559917).

None of this makes ghrelin-receptor peptides worse research tools. It makes them more interesting, and the picture honest: that receptor's natural ligand, in healthy men, went with less LH and less testosterone, not more. Compounds built on it are studied for growth hormone, appetite and cardiac biology; GHRP-2 vs GHRP-6 and Ipamorelin vs GHRP-2 explain how they differ.

Borrowing a Receptor: Where hCG Fits In

Human chorionic gonadotropin shows that the axis can be entered at any floor. It is not a research peptide Crown supplies; it is a hormone medicine licensed in the UK and many other countries, relevant here purely as context, because it binds the same receptor as LH. That receptor matters enough that when it does not work properly, Leydig cells fail to develop normally in males at all, and the two hormones sharing it are why it is properly called the lutropin/choriogonadotropin receptor (PMID: 11943741).

A retrospective German series of thirteen men with gonadotropin deficiency, in whom sperm production had already been established, switched them to hCG alone for three to 24 months. Sperm counts fell gradually but stayed present in all but one man, and their own LH and FSH were suppressed below the assay's detection limit (PMID: 12444893). Enter the axis at the testis and the floors above go quiet, exactly as a thermostat should.

The Loop That Closes, and Why the Axis Resists Being Pushed

One elegant experiment mapped the feedback arm. Frances Hayes and colleagues at Massachusetts General Hospital used a selective aromatase inhibitor to cut the conversion of testosterone to oestradiol, in parallel groups of fourteen normal men and seven men with idiopathic hypogonadotropic hypogonadism whose axis had been normalised with long-term GnRH. Oestradiol fell similarly in both groups, and testosterone rose by 53% in the normal men and 56% in the others.

The interesting part is what the pituitary did next. The gonadotropin rise was larger in the men with an intact hypothalamus — clearly so for FSH, 85% against 41%, and by a margin that just missed significance for LH, 100% against 58%. Frequent sampling in the normal men showed LH pulse frequency climbing from 10.2 to 14.0 pulses a day. The conclusion: oestrogen feeds back in two places, slowing GnRH pulses at the hypothalamus and damping the pituitary's response to them (PMID: 10999781).

The other half of the loop is just as decisive. A World Health Organization task force gave weekly testosterone to 271 healthy fertile men across ten centres in seven countries. Suppressing the axis from the bottom worked so thoroughly that 157 became azoospermic, a cumulative rate of 65% at six months, with a single pregnancy across 1,486 months of the efficacy phase, and sperm counts recovered within months of stopping (PMID: 1977002).

Put the two together and the shape is obvious. Add the end product from outside and the signals above switch off; remove the feedback and they speed up. A tightly regulated loop with its own set point — which is exactly why the peptides that interest researchers here are the ones that work with it rather than overriding it.

The Questions Nobody Has Answered Yet

This is a young field with obvious gaps, and the gaps are the most interesting part.

How is the pulse generator wired? Partly answered, and the partial answer is strange. A cluster of hypothalamic neurons carries kisspeptin, neurokinin B and dynorphin together, the KNDy neurons, and animal work suggests kisspeptin stimulates, neurokinin B modulates and dynorphin, an opioid, inhibits. The Imperial group tested that in humans for the first time, with eight study visits per volunteer and five men per group. Everything containing kisspeptin or the opioid blocker naltrexone strongly increased LH and LH pulsatility, and neurokinin B alone did nothing to gonadotropins — but neurokinin B combined with kisspeptin gave significantly smaller rises than kisspeptin alone (PMID: 27379743). Nobody has explained that.

What happens past twelve days? Nothing published says. The longest human kisspeptin protocol in the literature runs to twelve days (PMID: 42549827), and nobody has reported months. Almost all of the testosterone data comes from small groups of healthy young men with normal baselines, and the studies that enrolled men with hypogonadotropic hypogonadism used kisspeptin as a diagnostic probe rather than asking what sustained administration would do (PMID: 33227799).

And what about women? Every testosterone figure above comes from a male volunteer, so the same axis in women is mapped in a different currency. The one longer-acting kisspeptin receptor agonist with published human endocrine data, MVT-602, was studied in two randomised, placebo-controlled trials in healthy premenopausal women (PMID: 37925096). And nobody has compared how quickly KISS1R tires of a constant signal against how quickly the GnRH receptor does — the question all of the above keeps circling.

The Technical Breakdown: Two Decapeptides and Two Different Signals

The molecular detail, for readers who want it. Nothing above depends on it.

Two amidated decapeptides

GnRH is a ten-residue chain capped at both ends, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂, and gonadorelin is that sequence made synthetically. Kisspeptin-10 is also ten residues and also amidated: the C-terminal stretch of the parent protein, residues 112 to 121, which retains full intrinsic activity at the receptor (PMID: 21470997; PMID: 21632807). Kisspeptin-54 is the longer natural form, and the two behaved similarly head to head (PMID: 26089302). How the long-acting GnRH analogues are built out of that sequence, and why position 6 is the famous one, is in our Gonadorelin guide.

Why the signal changes currency twice

The GnRH receptor and KISS1R both work by raising calcium inside the cell they act on. The LH receptor does something different: it raises cyclic AMP inside the Leydig cell, which drives cholesterol into the mitochondrion and starts the enzymatic run to testosterone (PMID: 11943741). So the chain alternates — peptide, calcium, peptide, cyclic AMP, steroid — and the very last step is the only one that is not a peptide at all.

One Mass Unit Decides Which Molecule You Have

Short peptides are unforgiving. Gonadorelin and Kisspeptin-10 are both ten residues long with an amide at the C-terminus, and an amide is about one mass unit lighter than the free acid it replaces. Lose it in synthesis and you have a different molecule with a nearly identical name.

That is what the two tests on every batch certificate are for. The mass spectrometry line says which molecule turned up; the HPLC line says how much of the vial is that molecule and nothing else. Both are published on our Lab Reports page against the batch number printed on the vial, and How to Read a Peptide Certificate of Analysis and Peptide Testing UK walk through a real one line by line. Vials go out freeze-dried, cold and sealed, and our storage information covers keeping them that way. Order before 2pm on a weekday and it leaves that day; UK delivery costs nothing over £100. Questions go through our contact page, where a person answers, normally inside a working day and quicker on WhatsApp.

Related Compounds Worth Knowing About

The compounds researchers reach for when a question touches this territory, grouped by where they sit in the picture.

The reproductive axis itself

Gonadorelin Acetate is synthetic GnRH, the natural decapeptide, used to put a question directly to the pituitary. Kisspeptin-10 works a floor higher, through the GnRH neurons themselves. Oxytocin Acetate is the nine-amino-acid hypothalamic hormone, a useful counterpoint from the same region of the brain doing something entirely different; our Kisspeptin-10 vs Oxytocin comparison and Oxytocin guide set them against each other.

The growth hormone axis, and why it is a different conversation

Sermorelin and Tesamorelin are GHRH analogues, the natural fragment and the stabilised full-length version, and CJC-1295 (With DAC) is the long-acting one from the trial above. Ipamorelin, GHRP-2, GHRP-6 and Hexarelin Acetate work at the ghrelin receptor instead. Because the two receptor families are studied together, they are also offered paired, as CJC-1295 (No DAC) + Ipamorelin (Blend) and Tesamorelin + Ipamorelin (Blend); the reasoning is in CJC-1295 (No DAC) + Ipamorelin: The Two-Pathway Approach.

Downstream, and two frequently confused neighbours

IGF-1 LR3 and MGF sit below the growth hormone step, where the signal is read by tissue; our IGF-1 LR3 guide and Best Peptides Being Researched for Muscle Growth cover that end of the map. PT-141 came out of melanocortin chemistry and acts on a brain receptor, not the gonads (see PT-141: The First Melanocortin Receptor Agonist to Clear FDA Review), and DSIP belongs to the sleep side of endocrine research, where much of the body's own hormone pulsing happens (Best Peptides for Sleep Research).

Most of these sit together in our Endocrine & Hormonal research peptides category, and most of the growth hormone family also appears under Musculoskeletal research peptides. New to the field? Start with What Are Peptides?

The Rhythm Still Has Surprises Left In It

Fifty-five years after ten amino acids were read off a pig's hypothalamus, the system they govern is still handing out results nobody predicted. A peptide that resets a biological clock. An infusion that holds testosterone up but lets gonadotropins slide. A ghrelin pathway that quietens the reproductive axis while raising growth hormone.

What makes this corner of peptide science so rewarding is that the measurements are unambiguous. LH, FSH and testosterone can be sampled every few minutes, so the axis tells you straight away whether your intervention matched its rhythm or fought it. Few systems in biology answer that fast. If your own work is heading into the HPG axis, start at the top of the chain, with our Kisspeptin-10 Research Peptide and Gonadorelin Acetate Research Peptide, in our Endocrine & Hormonal research peptides range.

References

• Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978;202:631-3. PMID: 100883
• Wildt L, Häusler A, Marshall G, et al. Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology. 1981;109:376-85. PMID: 6788538
• Matsuo H, Baba Y, Nair RM, et al. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43:1334-9. PMID: 4936338
• Kastin AJ, Schally AV, Gual C, et al. Dose-response relationship of luteinizing hormone to luteinizing hormone--releasing hormone in man. J Clin Invest. 1971;50:1551-3. PMID: 4932985
• Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev. 2002;23:141-74. PMID: 11943741
• Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90:6609-15. PMID: 16174713
• George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96:E1228-36. PMID: 21632807
• Jayasena CN, Abbara A, Narayanaswamy S, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod. 2015;30:1934-41. PMID: 26089302
• Chan YM, Butler JP, Pinnell NE, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011;96:E908-15. PMID: 21470997
• Naveed A, Lippincott MF, Stamou M, et al. Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. Hormones (Athens). 2026. PMID: 42230485
• Yeung AC, Phylactou M, Koysombat K, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol. 2026;195:206-216. PMID: 42549827
• Abbara A, Eng PC, Phylactou M, et al. Kisspeptin-54 Accurately Identifies Hypothalamic Gonadotropin-Releasing Hormone Neuronal Dysfunction in Men with Congenital Hypogonadotropic Hypogonadism. Neuroendocrinology. 2021;111:1176-1186. PMID: 33227799
• Narayanaswamy S, Prague JK, Jayasena CN, et al. Investigating the KNDy Hypothesis in Humans by Coadministration of Kisspeptin, Neurokinin B, and Naltrexone in Men. J Clin Endocrinol Metab. 2016;101:3429-36. PMID: 27379743
• Abbara A, Ufer M, Voors-Pette C, et al. Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical trials. Fertil Steril. 2024;121:95-106. PMID: 37925096
• Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349:1614-27. PMID: 14573733
• Topaloglu AK, Tello JA, Kotan LD, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med. 2012;366:629-35. PMID: 22335740
• Hayes FJ, Seminara SB, Decruz S, et al. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab. 2000;85:3027-35. PMID: 10999781
• Kluge M, Schüssler P, Uhr M, et al. Ghrelin suppresses secretion of luteinizing hormone in humans. J Clin Endocrinol Metab. 2007;92:3202-5. PMID: 17550958
• Lanfranco F, Bonelli L, Baldi M, et al. Acylated ghrelin inhibits spontaneous luteinizing hormone pulsatility and responsiveness to naloxone but not that to gonadotropin-releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis. J Clin Endocrinol Metab. 2008;93:3633-9. PMID: 18559917
• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805. PMID: 16352683
• Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139:552-61. PMID: 9849822
• Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-70. PMID: 18057338
• Lanes R, Carrillo E. Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. Venezuelan Collaborative Study Group. J Pediatr Endocrinol. 1994;7:303-8. PMID: 7735367
• . Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311:1281-6. PMID: 6436700
• Santen RJ, Warner B. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate. Urology. 1985;25:53-7. PMID: 3918377
• Depenbusch M, von Eckardstein S, Simoni M, et al. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol. 2002;147:617-24. PMID: 12444893
• . Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990;336:955-9. PMID: 1977002